---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-027494"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T06:14:17.289344+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ARCA biopharma Q2 net loss narrows to $3.1M; strategic review ongoing

## Summary
- Net loss $3.1M ($0.22/sh) vs $4.8M ($0.34/sh) year ago.
- Cash and equivalents $46.4M as of June 30, 2022, sufficient through end of 2023.
- R&D expenses fell to $1.5M from $3.6M due to completion of rNAPc2 trial enrollment.
- Strategic review with advisor Ladenburg Thalmann; exploring acquisition, merger, or other options.
- G&A expenses $1.7M, up $0.5M on higher professional fees and consulting costs.

## SEC filing metadata
- accession: 0001564590-22-027494
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000156459022027494/0001564590-22-027494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000156459022027494/abio-8k_20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-027494
- JSON: https://secwatch.observer/filing/0001564590-22-027494.json
- Plain text: https://secwatch.observer/filing/0001564590-22-027494.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.